Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Snehal Palwe"'
Publikováno v:
Burns Open, Vol 4, Iss 4, Pp 160-166 (2020)
Objectives: his study was aimed to identify diverse β-lactamase genes produced by multiple drug-resistant Pseudomonas aeruginosa isolates procured from burn/wound infected patients hospitalized in General Al-thawrah hospital of Hodeidah city, Yemen
Externí odkaz:
https://doaj.org/article/5ea92a7d7fc94058849b1ba893bcd70a
Autor:
Snehal Palwe, Yamuna Devi Bakthavatchalam, Kshama Khobragadea, Arun S. Kharat, Kamini Walia, Balaji Veeraraghavan
Publikováno v:
Antibiotics, Vol 10, Iss 11, p 1318 (2021)
Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we ass
Externí odkaz:
https://doaj.org/article/b393954d1a6143759452cbbd2c6768ea
Publikováno v:
Microorganisms, Vol 8, Iss 10, p 1626 (2020)
The production of diverse and extended spectrum β-lactamases among Escherichia coli and ESKAPE pathogens is a growing threat to clinicians and public health. We aim to provide a comprehensive analysis of evolving trends of antimicrobial resistance a
Externí odkaz:
https://doaj.org/article/c8296e281811432491db7e7349c50547
Publikováno v:
Burns Open, Vol 4, Iss 4, Pp 160-166 (2020)
Objectives his study was aimed to identify diverse β-lactamase genes produced by multiple drug-resistant Pseudomonas aeruginosa isolates procured from burn/wound infected patients hospitalized in General Al-thawrah hospital of Hodeidah city, Yemen d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589a6fb656fd38a84bf5eb18d119458b
http://www.sciencedirect.com/science/article/pii/S2468912220300407
http://www.sciencedirect.com/science/article/pii/S2468912220300407
Autor:
Hellenic Cefepime, Rahul Shrivastava, Snehal Palwe, Sachin Bhagwat, Stylianos Chatzipanagiotou, Christos Goumenopoulos, Tilemachos Skalidis, Nicholas J. Legakis, Anastassios Loannidis, Hariharan Periasamy, Prashant Joshi, Mahesh Vithalbhai Patel
Publikováno v:
Diagnostic microbiology and infectious disease. 100(3)
Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a213ababe3bae1004f0e3882216c7c3d
https://pubmed.ncbi.nlm.nih.gov/33744624
https://pubmed.ncbi.nlm.nih.gov/33744624
Autor:
Rajeev Soman, Balaji Veeraraghavan, Yamuna Devi Bakthavatchalam, Mahesh Vithalbhai Patel, Periasamy Hariharan, Sachin Bhagwat, Prashant Joshi, Mayur Ramesh, Snehal Palwe, Naveen Kumar Devanga Ragupathi, Rahul Shrivastava
Publikováno v:
The Journal of antimicrobial chemotherapy. 75(12)
Background Recent reports reveal the emergence of Escherichia coli isolates harbouring a novel resistance mechanism based on four-amino-acid inserts in PBP3. These organisms concomitantly expressed ESBLs or/and serine-/metallo-carbapenemases and were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feaf9f2de0ed3b9f5ffdee6600c8d1d3
https://pubmed.ncbi.nlm.nih.gov/32772098
https://pubmed.ncbi.nlm.nih.gov/32772098
Publikováno v:
Antimicrob Agents Chemother
In India and China, indigenous drug manufacturers market arbitrarily combined parenteral β-lactam and β-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d7e66adb4cd0ac6f70caf057c31fa27
https://doi.org/10.1128/aac.00168-20
https://doi.org/10.1128/aac.00168-20
Autor:
Prashant Joshi, Mahesh Patel, Hariharan Periasamy, Rahul Shrivastava, Snehal Palwe, Sachin Bhagwat
Publikováno v:
The Journal of antimicrobial chemotherapy. 75(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07351f7cf663642e56b2c457e9c61734
https://pubmed.ncbi.nlm.nih.gov/32040179
https://pubmed.ncbi.nlm.nih.gov/32040179
Autor:
Balaji Veeraraghavan, Snehal Palwe, Kamini Walia, Arun S. Kharat, Kshama Khobragadea, Yamuna Devi Bakthavatchalam
Publikováno v:
Antibiotics, Vol 10, Iss 1318, p 1318 (2021)
Antibiotics
Volume 10
Issue 11
Antibiotics
Volume 10
Issue 11
Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbef2efa2a8dd5460886790e0076557a
https://doi.org/10.3390/antibiotics10111318
https://doi.org/10.3390/antibiotics10111318
Autor:
Swapna Shripad Takalkar, Snehal Palwe, Sachin Bhagwat, Mahesh Vithalbhai Patel, Hariharan Periasamy, H N Khande
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
WCK 5222 is a combination of cefepime and the high-affinity PBP2-binding β-lactam enhancer zidebactam. The cefepime-zidebactam combination is active against multidrug-resistant Gram-negative bacteria, including carbapenemase-expressing Acinetobacter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca6006630ea316ec279cb916469eb63d
https://doi.org/10.1128/aac.02146-18
https://doi.org/10.1128/aac.02146-18